Medicamen Biotech reports flat standalone profit for FY26
The pharmaceutical firm posted consolidated profit of ₹979.64 lacs, while standalone profit remained nearly flat at ₹940.87 lacs.
What's new
- Consolidated profit after tax rose to ₹979.64 lacs from ₹655.57 lacs in the prior year.
- Standalone revenue grew by 18% during the fiscal year.
- The board recommended a final dividend of ₹1.00 per share.
Why this matters
These results are a routine annual disclosure for a nano-cap firm. The lack of earnings surprises or strategic shifts suggests the company is tracking to its expected operational baseline.
What we're watching
- Future revenue growth trends beyond the 18% standalone increase.
- Any changes to the dividend payout policy in subsequent years.
- Operational updates that could move the needle for a nano-cap entity.
The full read
Medicamen Biotech released its audited annual results for FY26. The numbers show a mix of growth and stability.
Standalone revenue grew by 18%, yet standalone net profit remained nearly flat at ₹940.87 lacs. On a consolidated basis, profit after tax climbed to ₹979.64 lacs from ₹655.57 lacs in the prior year. The board recommended a final dividend of ₹1.00 per share, maintaining the payout level from the previous year despite an increased share count.
This filing is a routine periodic disclosure. There were no unexpected earnings surprises, guidance changes, or material strategic developments. For a nano-cap pharmaceutical company, these figures represent scheduled information rather than market-moving news. It is a quiet year.
Questions answered
- How did Medicamen Biotech perform in FY26?
- The company saw 18% standalone revenue growth. Consolidated profit reached ₹979.64 lacs, up from ₹655.57 lacs in the previous year.
- What was the standalone profit performance?
- Standalone net profit was nearly flat at ₹940.87 lacs for the year.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹1.00 per share. This is consistent with the payout from the previous year.
- Are these results unexpected?
- No. These are routine annual results that the market would have largely anticipated as part of the standard reporting calendar.